Redwood City, CA – According to filings with the U.S. Securities and Exchange Commission, Ashvattha Therapeutics is raising $9,564,619.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Jeffrey Cleland played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Ashvattha Therapeutics

Ashvattha Therapeutics are harnessing the power of Hydroxyl Dendrimers (HDs) to create a new class of precision medicine to heal patients. Ashvattha Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel hydroxyl dendrimer (HD) therapeutics (HDTs) to treat unmet medical needs in oncology, ophthalmology, and inflammatory diseases. We believe that HDTs will become the future of targeted therapeutics and unlock new levels of patient care. Ashvattha Therapeutics holds the exclusive rights to a novel hydroxyl dendrimer technology developed at Johns Hopkins University enabling a new class of targeted therapies previously unachievable with traditional drug moieties. Ashvattha are commercializing the technology through new entities established to develop therapeutic opportunities within specific fields and enabled through the use of our dendrimer platform.

To learn more about Ashvattha Therapeutics, visit http://www.ashvatthatherapeutics.com/

Contact:
Jeffrey Cleland, President and Chief Executive Officer
650-868-5853
jeffrey@ashvatthatherapeutics.com
https://www.linkedin.com/in/jeffrey-cleland-633574/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved